News

06.05.2022

Global Vaccine Hub「KHUB Science Park」Full-scale Promotion in Pohang City

– Hanmi Pharmaceutical President, Lim Chong-yoon, established a public interest foundation for a global standard vaccine research and production facility in Pohang City. – Pohang city is expected to grow as a center for bio/vaccine/healthcare research and production. Pohang City announced that KHUB Science Park, which is a non-profit public interest research foundation led by the president of Hanmi Pharmaceutical […]
24.02.2022

Hanmi Pharm Set to Produce COVID-19 Treatment for Merck and Supply to Developing Countries

Hanmi Pharmaceutical is set to manufacture a generic drug of Merck’s oral COVID-19 treatment drug and supply it to underdeveloped countries. On January 20th, Hanmi Pharmaceutical announced that it has recently signed a production agreement with the Medicines Patent Pool (MPP) for granting the right to produce molnupiravir (brand name: Lagevrio) developed by Merck of the United States. Under this […]
07.02.2022

Hanmi Pharm Set to Produce DNA-based COVID-19 Vaccine Developed by Zydus Cadila

Hanmi Pharmaceutical announced that it would begin the production of ZyCoV-D, the COVID-19 plasmid DNA vaccine, developed by Indian pharmaceutical company Zydus Cadila (Zydus). To this end, Hanmi Pharm signed a contract for the technology transfer and facility preparation for consignment manufacturing of the ZyCoV-D vaccine with Enzychem Life Sciences on January 7. Enzychem signed a technology transfer agreement with […]
16.11.2021

Chong Yoon Lim, CEO of Hanmi Science, announces addition of eWorldwide Group to Hanmi Science Consortium and invites other groups to join

As G20 Explores Vaccine Equity, Hanmi Science Consortium Pushes Forward with Vaccine Equity Initiative. In his recent opening address to the G20, Italian Prime Minister Mario Draghi highlighted vaccine inequity, emphasizing the fact that only 3% of eligible people living in the world’s poorest nations had received any form of COVID-19 vaccine, versus more than 70% in high-income countries. Mr. […]
07.09.2021

Hanmi Pharmaceutical Makes Turnaround in Second Quarter with 120% Growth in Sales

Hanmi Pharmaceutical’s growth momentum continued with its operating profit climbing 49.6% in the second quarter. Beijing Hanmi Pharmaceutical, which had taken a severe blow from COVID-19, successfully achieved a turnaround with its sales rising 119.9% year-over-year. Hanmi Pharmaceutical posted a temporary notice stating that it achieved EUR 0.2 billion in sales, EUR 11.6 million in operating profit, and EUR 0.6 […]
06.07.2021

Korea National Institute of Health (KNIH) conducts field inspection of companies with mRNA technology

Korea National Institute of Health (KNIH), Korea’s top research center in the field of hygiene and medicine (with Mr. Kwon Jun-Wook as President) conducted a field inspection of key companies with mRNA technology.   KNIH visited Hanmi Fine Chemical which is a company specializing in raw materials, which is a subsidiary of Hanmi Pharmaceutical Group and specializes in pharmaceutical products […]
12.01.2021

1 Billion Doses a Year – It Will Become an Outpost for the Consigned Production of a Covid-19 Vaccine

Image Source: Hanmi Bio Plant   It was confirmed that global pharmaceutical companies developing Covid-19 vaccines have tried to reach Hanmi Pharm., as the production capability of Hanmi Bio Plant has drawn much attention.   “At the Hanmi Bio Plant, it is possible to produce annually the vaccine of a maximum of 1 billion doses. It could play a major […]
24.09.2020

US FDA Designates Fast Track for Hanmi Pharm’s “LAPS Triple Agonist”

According to Hanmi Pharm, the US Food and Drug Administration (FDA) has designated LAPS Triple Agonist (HM15211), an innovative drug for the treatment of NASH (non-alcoholic steatohepatitis) manufactured by Hanmi, as a Fast Track drug. FDA generally designates the drug as “fast track” drugs when considering it must be developed quickly after the careful examination of new drugs with good […]
22.04.2020

Babies and Covid19: the pharmaceutical giant COREE donates 150 thousand euros to 5 Italian hospitals.

Babies and Covid 19, only a few cases, but immediately on the front pages of newspapers. Coree, a giant in the Korean pharmaceutical sector and leader in Asia in the field of neonatal care, has decided to support the pediatricians of 5 Italian hospitals during the emergency. In a few days Coree, the Italian branch of Hanmi Pharmaceutical in Seoul, which […]
18.12.2019

Chongyoon Lim’s Representative Departed to China and Italy to Unveil the “Second Act” of Hanmi Pharm’s Development

Chongyoon Lim, the representative of Hanmi Science who started the cause of “total health care”, developed new drugs in China, explored targeted medical and health cooperation, and expanded relevant businesses in Italy. On November 25, representative Chongyoon Lim of Hanmi Science listened to In-seon Lee, director of Daegu-Gyeongbuk Free Economic Zone, explaining the support plan at the business contract ceremony […]
25.11.2019

Hanmi Science and Pohang University of Science and Technology (North Gyeongsang, South Korea) Join Hands to Develop New Drugs

Hanmi Science will make joint efforts with North Gyeongsang, Pohang City and Pohang University of Science and Technology (POSTECH) to develop new drugs. Hanmi Science executed an accelerator-based new drug development agreement with Pohang City and Pohang University of Science and Technology at POSTECH’s headquarters on the 25th. (From left) Dal-hee Lee, Head of the Government Office of North Gyeongsang […]
19.11.2019

COREE Group, an Affiliate of Hanmi Science, “Promotes FDA Approval of One-to-One Customized Health Platform”

COREE Group, an affiliate of Hanmi Science, will push its own platform, “life intervention”, into the US market with the ability to improve living habits and predict diseases. Its goal is to obtain a license for the medical software (SaMD•Software as Medical Device) from the Food and Drug Administration (FDA). It is undeniable that it will take several years to […]
EN
Freccia torna in alto